4.6 Review

Type 2 diabetes in adolescents and young adults

期刊

LANCET DIABETES & ENDOCRINOLOGY
卷 6, 期 1, 页码 69-80

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/S2213-8587(17)30186-9

关键词

-

资金

  1. Merck, Sharpe Dohme
  2. Novartis
  3. Boehringer Ingelheim
  4. Janssen
  5. AstraZeneca
  6. Novo Nordisk
  7. Eli Lilly
  8. Sanofi-Aventis
  9. Elcelyx
  10. Lexicon
  11. Poxel
  12. Binding Site

向作者/读者索取更多资源

The prevalence of type 2 diabetes in adolescents and young adults is dramatically increasing. Similar to older-onset type 2 diabetes, the major predisposing risk factors are obesity, family history, and sedentary lifestyle. Onset of diabetes at a younger age (defined here as up to age 40 years) is associated with longer disease exposure and increased risk for chronic complications. Young-onset type 2 diabetes also affects more individuals of working age, accentuating the adverse societal effects of the disease. Furthermore, evidence is accumulating that young-onset type 2 diabetes has a more aggressive disease phenotype, leading to premature development of complications, with adverse effects on quality of life and unfavourable effects on long-term outcomes, raising the possibility of a future public health catastrophe. In this Review, we describe the epidemiology and existing knowledge regarding pathophysiology, risk factors, complications, and management of type 2 diabetes in adolescents and young adults.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据